TOMI Environmental Solutions’ Binary Ionization Technology Approved in the Netherlands
Rhea-AI Summary
TOMI Environmental Solutions (NASDAQ: TOMZ) announced that its Binary Ionization Technology (BIT) Solution received formal authorization from the Dutch regulatory authority ctgb on March 24, 2026 as a PT2 disinfectant for professional indoor use using SteraMist room fogging and surface spraying equipment.
The approval, granted under the EU Biocidal Products Regulation (BPR), is TOMI's first product authorization in an EU member state and may support streamlined mutual recognition across twelve named EU countries. Netherlands partner Ster-Pharma (since 2019) is positioned to commercialize products quickly.
Positive
- First EU authorization obtained for BIT Solution (ctgb, March 24, 2026)
- Authorized as PT2 disinfectant for professional indoor use
- Mutual recognition pathway may cover 12 EU countries
- Established distribution partner Ster-Pharma since 2019 enables quick roll-out
Negative
- Authorization currently limited to the Netherlands only
- Regulatory process extended: initial UK submission in 2017, approval in 2026
News Market Reaction – TOMZ
On the day this news was published, TOMZ declined 4.95%, reflecting a moderate negative market reaction. Argus tracked a trough of -10.9% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $708K from the company's valuation, bringing the market cap to $13.59M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TOMZ was up 1.42% while peers showed mixed action: LIQT (-2.25%), CLIR (0%), CLWT (+2.63%), DEVS (-2.48%), ZONE (+6.88%). Momentum scanner flagged DEVS and RAIN both moving up, but this pattern does not indicate a unified sector move around TOMZ’s EU approval.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Food safety expansion | Positive | -2.7% | Announced SteraMist iHP entry into food safety with up to 95% test cost cuts. |
| Mar 16 | Canadian expansion | Positive | +5.3% | Reported wider SteraMist deployments across Canadian hospital and research systems. |
| Mar 03 | EU partner appointment | Positive | -2.8% | Named Total Clean Air as preferred European partner for SteraMist iHP. |
| Feb 23 | GB/NI approvals | Positive | +12.7% | Received GB and NI biocidal authorizations for BIT and SteraMist products. |
| Jan 20 | UK CES contract | Positive | +0.6% | Secured CES sale integrating SteraMist iHP into modular cleanroom platform. |
Positive regulatory and expansion news has often led to upside, but there are notable instances where similar positive updates were followed by short-term declines.
Over the past months, TOMI has reported multiple commercial and regulatory milestones, including UK and Northern Ireland biocidal approvals on Feb 23, 2026 and a UK CES cleanroom integration on Jan 20, 2026. Recent releases also highlighted Canadian healthcare expansion and a food safety push featuring up to a 95% cost reduction for a CPG partner. Today’s Netherlands BIT authorization continues this theme of international regulatory progress and EU-focused partnerships, building on earlier European positioning moves.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2025-11-14 allows TOMI to offer up to $50,000,000 in various securities over time. As of the latest data, usage_count is 0 with no recorded 424B takedowns, but a separate equity purchase arrangement permits sales of up to $20,000,000 of common stock over 24 months once effective.
Market Pulse Summary
This announcement detailed Dutch ctgb approval of TOMI’s BIT Solution as a PT2 disinfectant on March 24, 2026, creating a foothold in the EU under the Biocidal Products Regulation. It followed recent GB/NI authorizations and European partnerships, reinforcing a regulatory-led growth strategy. Investors may watch how quickly mutual recognition in other EU states converts into deployments and revenue, while also considering the existing $50,000,000 S-3 shelf and separate $20,000,000 equity facility as capital-raising tools.
Key Terms
binary ionization technology technical
biocidal products regulation (bpr) regulatory
AI-generated analysis. Not financial advice.
European Union Market Expansion Advances with Official Authorization
FREDERICK, Md., March 25, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that its Binary Ionization Technology has received formal approval from the Dutch regulatory authority Board (“ctgb”) for the Authorization of Plant Protection Products and Biocides, marking the Company's first product authorization within a European Union member state.
TOMI's Binary Ionization Technology (BIT) Solution has been officially authorized as a PT2 disinfectant. The authorization covers BIT Solution with both SteraMist room fogging and surface spraying equipment. The product is approved for professional indoor use across the Netherlands, addressing bacteria, yeasts, and mycobacteria serving the medical, healthcare, industrial, commercial, hospitality, institutional, and tertiary sectors. Originally submitted to UK HSE in 2017, and subsequently transferred to ctgb in 2020, the application received final approval on March 24, 2026.
This approval was granted under the European Union's Biocidal Products Regulation (BPR), the regulatory framework governing the authorization of biocidal products across all EU member states. Under BPR provisions, an approval secured in one member state can support a streamlined mutual recognition pathway in others, potentially accelerating TOMI's ability to bring BIT to market across the broader European Union without the need to repeat the full authorization process in each country. Mutual recognition in parallel is expected in the following countries: Austria, Belgium, Denmark, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania and Spain.
With an established partnership since 2019, Netherlands-based Ster-Pharma is positioned to move SteraMist iHP disinfection products quickly into key sectors now that formal authorization has been secured.
"Receiving approval in the Netherlands represents a major milestone in TOMI's European strategy," said Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI. "Our team maintained consistent engagement with the Ctgb throughout this process, and we are proud to see that commitment result in this authorization. We have opportunities across the European Union who have been eagerly anticipating this approval. We anticipate additional EU member states will follow, and with our established network across the region, we are well-positioned to deliver meaningful impact in the laboratory, healthcare, food, and other high-demand sectors that have long been awaiting final registration."
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the European market. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Zach Nevas
IMS Investor Relations
FAQ
What did TOMI (TOMZ) receive approval for in the Netherlands on March 24, 2026?
How does the Netherlands ctgb approval affect TOMI (TOMZ) expansion in the European Union?
Which countries are expected to pursue mutual recognition for TOMI's BIT after the Dutch approval?
What equipment and uses are covered by TOMI's BIT authorization in the Netherlands?
Will TOMI's Netherlands approval immediately allow sales across Europe for TOMZ products?
